In the US, the ASCO (American Society of Clinical Oncology) also recommends alpesilib with the additional statement that PIK3CA mutations can be detected in tumor tissue or cfDNA, but in case of a negative cfDNA result, tumor biopsy should be considered due to the higher variant allele frequency of potential mutations [269]. This evidence concerns the gene PIK3CA and neoplasm.